Results 11 to 20 of about 22,921 (208)

Safety and efficacy of azacitidine in myelodysplastic syndromes

Drug Design, Development and Therapy, 2010
Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAPurpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are ...
Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-Manero   +2 more
doaj   +2 more sources

Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model [PDF]

, 2016
INTRODUCTION. Decreased expression of highly immunogenic cancer-testis antigens (CTA) might help tumor to achieve low immunogenicity, escape immune surveillance and grow unimpeded. Our aim was to evaluate CTA expression in tumor and normal tissues and to
Goliadze, Ekaterine, Guruli, Georgi, Manjili, Masoud H., Petrossian, Albert A., Robinson, Samuel P., Sulek, Jay E., Toor, Amir, Zhou, Shaoqing   +7 more
core   +2 more sources

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine

Haematologica, 2022
Better understanding of the biology of resistance to DNA methyltransferase (DNMT) inhibitors is required to identify therapies that can improve their efficacy for patients with high-risk myelodysplastic syndrome (MDS).
Theodoros Karantanos, Patric Teodorescu, Marios Arvanitis, Brandy Perkins, Tania Jain, Amy E. DeZern, W. Brian Dalton, Ilias Christodoulou, Bogdan C. Paun, Ravi Varadhan, Christopher Esteb, Trivikram Rajkhowa, Challice Bonifant, Lukasz P. Gondek, Mark J. Levis, Srinivasan Yegnasubramanian, Gabriel Ghiaur, Richard J. Jones   +17 more
doaj   +1 more source

Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells [PDF]

, 2012
DNA methylation might be the earliest somatic genome changes in prostate cancer that also play an important role in the process of tumor invasion, growth and metastasis.
D'Alessandro, Anna Maria, Di Clemente, Luigi, Di Pasquale, Boris, Dolo, Vincenza, Festuccia, Claudio, Gravina, Giovanni Luca, Mancini, Andrea, Marampon, Francesco, Muzi, Paola, Ranieri, Guido   +9 more
core   +1 more source

A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

Haematologica, 2016
The efficacy of azacitidine in patients with anemia and with lower-risk myelodysplastic syndromes, if relapsing after or resistant to erythropoietic stimulating agents, and the benefit of combining these agents to azacitidine in this setting are not well
Sylvain Thépot, Raouf Ben Abdelali, Sylvie Chevret, Aline Renneville, Odile Beyne-Rauzy, Thomas Prébet, Sophie Park, Aspasia Stamatoullas, Agnes Guerci-Bresler, Stéphane Cheze, Gérard Tertian, Bachra Choufi, Laurence Legros, Jean Noel Bastié, Jacques Delaunay, Marie Pierre Chaury, Laurence Sanhes, Eric Wattel, Francois Dreyfus, Norbert Vey, Fatiha Chermat, Claude Preudhomme, Pierre Fenaux, Claude Gardin   +23 more
doaj   +1 more source

HDAC inhibition potentiates immunotherapy in triple negative breast cancer. [PDF]

, 2017
Triple-negative breast cancer (TNBC) represents a more aggressive and difficult subtype of breast cancer where responses to chemotherapy occur, but toxicity is significant and resistance often follows. Immunotherapy has shown promising results in various
Ali, Niwa, Budillon, Alfredo, Krings, Gregor, Munster, Pamela N, Park, Jeenah, Pawlowska, Nela, Rosenblum, Michael D, Terranova-Barberio, Manuela, Thomas, Scott   +8 more
core   +1 more source

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia

Haematologica, 2019
Standard treatment for higher risk myelodysplastic syndromes, chronic myelomonocytic leukemia and low blast acute myeloid leukemia is azacitidine. In single arm studies, adding lenalidomide had been suggested to improve outcomes.
Melita Kenealy, Mark Hertzberg, Warwick Benson, Kerry Taylor, Ilona Cunningham, Will Stevenson, Devendra Hiwase, Richard Eek, Daniela Zantomio, Steve Jong, Meaghan Wall, Piers Blombery, Tracey Gerber, Marlyse Debrincat, Diana Zannino, John F. Seymour   +15 more
doaj   +1 more source

Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis

Neoplasia: An International Journal for Oncology Research, 2021
During progression of myeloid neoplasms, the basophil compartment may expand substantially and in some of these patients, a basophilic leukemia is diagnosed.
Daniela Berger, Karin Bauer, Christoph Kornauth, Susanne Gamperl, Gabriele Stefanzl, Dubravka Smiljkovic, Christian Sillaber, Peter Bettelheim, Paul Knöbl, Ana-Iris Schiefer, Georg Greiner, Renate Thalhammer, Gregor Hoermann, Ilse Schwarzinger, Philipp B. Staber, Wolfgang R. Sperr, Peter Valent   +16 more
doaj   +1 more source

Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. [PDF]

, 2015
BackgroundDemethylation process is necessary for the expression of various factors involved in chemotherapy cytotoxicity or resistance. Platinum-resistant cells may have reduced expression of the copper/platinum transporter CTR1.
Culotta, Kirk, Falchook, Gerald, Fu, Siqing, He, Guangan, Hess, Kenneth, Issa, Jean-Pierre J, Jelinek, Jaroslav, Kurzrock, Razelle, Naing, Aung, Piha-Paul, Sarina, Said, Rabih, Siddik, Zahid H, Stewart, David J, Tsimberidou, Apostolia M, Wistuba, Ignacio, Zinner, Ralph   +15 more
core   +2 more sources

A Jehovah’s Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions

Case Reports in Hematology, 2014
Therapy for acute leukemia in Jehovah’s Witnesses patients is very challenging because of their refusal to accept blood transfusions, a fundamental supportive therapy for this disease.
Yumi Yamamoto, Akihito Kawashima, Eri Kashiwagi, Kiyoyuki Ogata   +3 more
doaj   +1 more source